A Multicenter, Nonrandomized, Open-Label Phase 1 Safety Study of HspE7 and Poly-ICLC Administered Concomitantly in Cervical Intraepithelial Neoplasia (CIN) Subjects

Trial Profile

A Multicenter, Nonrandomized, Open-Label Phase 1 Safety Study of HspE7 and Poly-ICLC Administered Concomitantly in Cervical Intraepithelial Neoplasia (CIN) Subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 08 Oct 2008

At a glance

  • Drugs Verpasep caltespen (Primary) ; Poly ICLC
  • Indications Cervical cancer; Cervical intraepithelial neoplasia; Human papillomavirus infections
  • Focus Adverse reactions
  • Sponsors Nventa Biopharmaceuticals Corporation
  • Most Recent Events

    • 08 Oct 2008 Status changed from active, no longer recruiting to completed.
    • 28 Jul 2008 Analysis of immunological data from all four cohorts reported in a Nventa media release.
    • 12 May 2008 Immunological data from the third cohort reported in an Nventa medial release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top